Impact of ABCB1 C3435T Polymorphism on Treatment Response of Vitamin K Antagonists: A Systematic Review and Meta-analysis

다국어 초록 (Multilingual Abstract)

Objective: The aim of this study was to examine the impact of ATP-binding cassette subfamily B member 1 (ABCB1) C3435Tpolymorphism on the treatment response of patients to vitamin K antagonists (VKAs). Methods: In this systematic review and metaanalysis,the PubMed/Medline, Embase, and Cochrane Library databases were searched for eligible articles for the period up toNovember 2020. Articles that reported treatment response to VKAs according to the ABCB1 C3435T polymorphism were includedin this study. Results: A total of 13 and 9 articles were included in the systematic review and meta-analysis, respectively. The weeklymaintenance dose of warfarin was significantly lower in patients with the ABCB1 3435CT or TT polymorphism type than in thosewith the ABCB1 3435CC type (weighted mean difference [WMD], −2.53 mg/week; 95% confidence interval [CI], −3.64 to −1.43,p<0.001). However, the weekly maintenance dose of acenocoumarol was not significantly associated with the ABCB1 C3435Tpolymorphism (WMD, 1.02; 95% CI, −0.61 to 2.65, p=0.22). Conclusion: The ABCB1 C3435T polymorphism was significantlyassociated with the weekly maintenance dose of warfarin. Further research is needed to confirm the association between the ABCB1C3435T polymorphism and the incidence rate of bleeding events.

참고문헌 (Reference)

1 Campos EIF, "Weekly warfarin maintenance dose according to variations in four genes evaluated in patients assisted at a Brazilian anticoagulation clinic" 2 (2): 230-231, 2018

2 Wadelius M, "Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1(MDR1)and other factors" 4 (4): 40-48, 2004

3 Mueller JA, "Warfarin dosing and body mass index" 48 (48): 584-588, 2014

4 Nutescu EA, "Warfarin and its interactions with foods, herbs and other dietary supplements" 5 (5): 433-451, 2006

5 Zhu J, "Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017" 38 (38): 907-920, 2018

6 Sychev DA, "The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation" 31 (31): 173-178, 2016

7 Wessler JD, "The P-glycoprotein transport system and cardiovascular drugs" 61 (61): 2495-2502, 2013

8 Wells G, "The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis"

9 Holbrook AM, "Systematic overview of warfarin and its drug and food interactions" 165 (165): 1095-1106, 2005

10 Miyasaka Y, "Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence" 114 (114): 119-125, 2006

11 Gschwind L, "Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model" 113 (113): 259-265, 2013

12 Demirkan K, "Response to warfarin and other oral anticoagulants : effects of disease states" 93 (93): 448-454, 2000

13 Go AS, "Prevalence of diagnosed atrial fibrillation in adults : national implications for rhythm management and stroke prevention : the AnTicoagulation and Risk Factors in Atrial Fibrillation(ATRIA)Study" 285 (285): 2370-2375, 2001

14 Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement" 339 : b2535-, 2009

15 Jiménez-Varo E, "Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm" 24 (24): 501-513, 2014

16 Bruhn O, "Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance" 10 (10): 1337-1354, 2014

17 de Oliveira Almeida VC, "Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study" 18 (18): 675-683, 2014

18 Whirl-Carrillo M, "Pharmacogenomics knowledge for personalized medicine" 92 (92): 414-417, 2012

19 Saraeva RB, "Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements" 32 (32): 641-649, 2007

20 White PJ, "Patient factors that influence warfarin dose response" 23 (23): 194-204, 2010

21 Gschwind L, "P-glycoprotein : a clue to vitamin K antagonist stabilization" 16 (16): 129-136, 2015

22 Luo D, "Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range" 27 (27): 1785-1805, 2018

23 Wang D, "Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability" 15 (15): 693-704, 2005

24 Silva R, "Modulation of P-glycoprotein efflux pump : induction and activation as a therapeutic strategy" 149 : 1-123, 2015

25 Zhai Y, "Meta-analysis of effects of ABCB1polymorphisms on clopidogrel response among patients with coronary artery disease" 73 (73): 843-854, 2017

26 Fung KL, "MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer" 74 (74): 598-608, 2014

27 Yanik MV, "Influence of kidney transplant status on warfarin dose, anticoagulation control, and risk of hemorrhage" 37 (37): 1366-1373, 2017

28 Ajmi M, "Influence of genetic and nongenetic factors on acenocoumarol maintenance dose requirement in a Tunisian population" 74 (74): 711-722, 2018

29 Shendre A, "Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage" 38 (38): 588-596, 2018

30 Wolking S, "Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: Update of the literature" 54 (54): 709-735, 2015

31 Li W, "Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients" 21 (21): 101-110, 2020

32 Vahedi S, "Global alteration of the drugbinding pocket of human P-glycoprotein(ABCB1)by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency" 143 : 53-64, 2017

33 Shou W, "Gene-wide characterization of common quantitative trait loci for ABCB1 mRNA expression in normal liver tissues in the Chinese population" 7 (7): e46295-, 2012

34 Rojo M, "Functionally significant coumarin-related variant alleles and time to therapeutic range in Chilean cardiovascular patients" 26 : 1076029620909154-, 2020

35 Ieiri I, "Functional significance of genetic polymorphisms in Pglycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2)" 27 (27): 85-105, 2012

36 Park MW, "Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians" 18 (18): 833-841, 2016

37 Wan X, "Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range" 14 : 135-, 2014

38 Nakamura T, "Effect of the mutation(C3435T)at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects" 71 (71): 297-303, 2002

39 Bonde AN, "Effect of reduced renal function on time in therapeutic range among anticoagulated atrial fibrillation patients" 69 (69): 752-753, 2017

40 Elkhazraji A, "Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients" 12 (12): 68-76, 2018

41 Xie Q, "Effect of ABCB1 genotypes on the pharmacokinetics and clinical outcomes of new oral anticoagulants : a systematic review and meta-analysis" 24 (24): 3558-3565, 2018

42 Issac MS, "EPHX1 and protein Z gene variants in modulation of warfarin dosage?" 18 (18): 73-83, 2014

43 Becker ML, "Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol" 76 (76): 1457-1464, 2020

44 Higgins JPT, "Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020)"

45 Johnson JA, "Clinical Pharmacogenetics Implementation Consortium(CPIC)guideline for pharmacogeneticsguided warfarin dosing : 2017 update" 102 (102): 397-404, 2017

46 Kim Y, "C3435T polymorphism of MDR1 gene with warfarin resistance" 425 : 34-36, 2013

47 Peng LL, "Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy" 37 (37): 1442-1448, 2016

48 Ferrari M, "Association between ABCG2 and ABCB1 genes and warfarin stability : a case-control study" 134 (134): 1359-1362, 2014

49 Tavares LC, "Association between ABCB1 polymorphism and stable warfarin dose requirements in brazilian patients" 9 : 542-, 2018

50 Kimchi-Sarfaty C, "A "silent" polymorphism in the MDR1 gene changes substrate specificity" 315 (315): 525-528, 2007